{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:46:25Z","timestamp":1760150785436,"version":"build-2065373602"},"reference-count":51,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T00:00:00Z","timestamp":1703980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Curcumin, a major constituent of turmeric (Curcuma longa L.), has beneficial effects against several diseases. In cystic fibrosis (CF), this compound improves patients\u2019 symptoms by recovering the activity of a number of mutants of the cystic fibrosis transmembrane conductance regulator (CFTR). Despite holding promise in the treatment of CF, the curcumin binding site in CFTR and the molecular mechanism of activation of this channel are still unknown. The results of this study, based on docking and molecular dynamics (MD) simulations, allow us to propose that curcumin binds the closed ATP-free CFTR near the nucleotide-binding domain 1 (NBD1)\/ICl1\/ICl4 interface. The bound ligand, once approached by the nucleotide-binding domain 2 (NBD2) during transient channel opening, lays at a multiple interdomain cross point. Thereafter, curcumin can bridge NBD1 and NBD2, and also ICL1\/ICL4 and ICL2\/ICL3, finally tightening the same interdomain interactions that normally uphold the open conformation in the wild-type ATP-bound CFTR. The proposed binding site is compatible with biochemical observations made in previous CFTR\u2013curcumin interaction studies. These findings provide a framework for the design of novel drugs that activate CFTR mutants characterized by defects in ATP binding and\/or NBD dimerization or even lacking NBD2.<\/jats:p>","DOI":"10.3390\/ijms25010552","type":"journal-article","created":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T06:37:12Z","timestamp":1704004632000},"page":"552","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exploring the Mechanism of Activation of CFTR by Curcuminoids: An Ensemble Docking Study"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2757-849X","authenticated-orcid":false,"given":"Emanuele","family":"Bellacchio","sequence":"first","affiliation":[{"name":"Genetica Molecolare e Genomica Funzionale, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, 00165 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"28463","DOI":"10.1074\/jbc.271.45.28463","article-title":"ATPase activity of the cystic fibrosis transmembrane conductance regulator","volume":"271","author":"Li","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1073\/pnas.100588797","article-title":"A functional R domain from cystic fibrosis transmembrane conductance regulator is predominantly unstructured in solution","volume":"97","author":"Ostedgaard","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/0092-8674(91)90446-6","article-title":"Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel","volume":"66","author":"Cheng","year":"1991","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1469-7793.1998.365bq.x","article-title":"Di-basic protein kinase A sites regulate bursting rate and nucleotide sensitivity of the cystic fibrosis transmembrane conductance regulator chloride channel","volume":"508","author":"Mathews","year":"1998","journal-title":"J. Physiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1038\/sj.emboj.7601373","article-title":"In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer","volume":"25","author":"Mense","year":"2006","journal-title":"EMBO J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1113\/jphysiol.2002.035790","article-title":"Phosphorylation of protein kinase C sites in NBD1 and the R domain control CFTR channel activation by PKA","volume":"548","author":"Chappe","year":"2003","journal-title":"J. Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1074\/jbc.M609942200","article-title":"Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains","volume":"282","author":"Wang","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jmb.2006.10.086","article-title":"Domain interdependence in the biosynthetic assembly of CFTR","volume":"365","author":"Cui","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1146\/annurev.ge.29.120195.004021","article-title":"Cystic fibrosis: Genotypic and phenotypic variations","volume":"29","author":"Zielenski","year":"1995","journal-title":"Annu. Rev. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Cystic fibrosis since 1938","volume":"173","author":"Davis","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Bacalhau, M., Camargo, M., Magalh\u00e3es-Ghiotto, G.A.V., Drumond, S., Castelletti, C.H.M., and Lopes-Pacheco, M. (2023). Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis. Pharmaceuticals, 16.","DOI":"10.3390\/ph16030410"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.2174\/13816128113199990320","article-title":"Curcumin and genistein: The combined effects on disease-associated CFTR mutants and their clinical implications","volume":"19","author":"Sohma","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/biof.1960","article-title":"Therapeutic potential of phytochemicals for cystic fibrosis","volume":"49","author":"Baharara","year":"2023","journal-title":"Biofactors"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcf.2011.03.001","article-title":"Curcumin and genistein additively potentiate G551D-CFTR","volume":"10","author":"Yu","year":"2011","journal-title":"J. Cyst. Fibros."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jcf.2016.04.007","article-title":"Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations","volume":"15","author":"Dekkers","year":"2016","journal-title":"J. Cyst. Fibros."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1093941","article-title":"Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects","volume":"304","author":"Egan","year":"2004","journal-title":"Science"},{"key":"ref_17","first-page":"76","article-title":"Cystic fibrosis bench to bedside for Curcuma longa L. in cystic fibrosis\u2014Curcumin\u2019s controversial role as therapy","volume":"4","author":"Henke","year":"2008","journal-title":"US Respir. Dis."},{"key":"ref_18","first-page":"1054","article-title":"Natural Compounds as Therapeutic Agents to Treat Cystic Fibrosis","volume":"4","author":"Dey","year":"2016","journal-title":"JSM Gastroenterol. Hepatol."},{"key":"ref_19","first-page":"2895","article-title":"Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions","volume":"21","author":"Cheng","year":"2001","journal-title":"Anticancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/S0731-7085(96)02024-9","article-title":"Stability of curcumin in buffer solutions and characterization of its degradation products","volume":"15","author":"Wang","year":"1997","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.saa.2014.05.096","article-title":"The effect of the water on the curcumin tautomerism: A quantitative approach","volume":"132","author":"Manolova","year":"2014","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15504","DOI":"10.1039\/C9CP00907H","article-title":"Interplay between conformational and solvent effects in UV-visible absorption spectra: Curcumin tautomers as a case study","volume":"21","author":"Puglisi","year":"2019","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11974","DOI":"10.1021\/acs.jafc.8b03893","article-title":"Keto-Enol Tautomerism of Temperature and pH Sensitive Hydrated Curcumin Nanoparticles: Their Role as Nanoreactors and Compatibility with Blood Cells","volume":"66","author":"Kaur","year":"2018","journal-title":"J. Agric. Food Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40204-022-00198-3","article-title":"Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis","volume":"11","author":"Quispe","year":"2022","journal-title":"Prog. Biomater."},{"key":"ref_25","first-page":"11169","article-title":"Effects of Curcumin Supplementation on Quality of Life of Cystic Fibrosis Patients","volume":"8","author":"Rafeey","year":"2020","journal-title":"Int. J. Pediatr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1021\/acs.biochem.5b00219","article-title":"Molecular Basis for Fe(III)-Independent Curcumin Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Activity","volume":"54","author":"Wang","year":"2015","journal-title":"Biochemistry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jmgm.2008.12.005","article-title":"Molecular modeling of the heterodimer of human CFTR\u2019s nucleotide-binding domains using a protein-protein docking approach","volume":"27","author":"Huang","year":"2009","journal-title":"J. Mol. Graph. Model."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.chembiol.2013.06.004","article-title":"Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction","volume":"20","author":"Farinha","year":"2013","journal-title":"Chem. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1096\/fj.12-216119","article-title":"Correctors of \u0394F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein","volume":"27","author":"He","year":"2013","journal-title":"FASEB J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nchembio.1253","article-title":"Mechanism-based corrector combination restores \u0394F508-CFTR folding and function","volume":"9","author":"Okiyoneda","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1124\/mol.117.108373","article-title":"Direct Binding of the Corrector VX-809 to Human CFTR NBD1: Evidence of an Allosteric Coupling between the Binding Site and the NBD1:CL4 Interface","volume":"92","author":"Hudson","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/prot.25496","article-title":"Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site","volume":"86","author":"Molinski","year":"2018","journal-title":"Proteins"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Righetti, G., Casale, M., Liessi, N., Tasso, B., Salis, A., Tonelli, M., Millo, E., Pedemonte, N., Fossa, P., and Cichero, E. (2020). Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218084"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Parodi, A., Righetti, G., Pesce, E., Salis, A., Tomati, V., Pastorino, C., Tasso, B., Benvenuti, M., Damonte, G., and Pedemonte, N. (2022). Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays. Pharmaceuticals, 15.","DOI":"10.3390\/ph15030274"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cell.2021.12.009","article-title":"Mechanism of CFTR correction by type I folding correctors","volume":"185","author":"Fiedorczuk","year":"2022","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.aaw7611","article-title":"Structural identification of a hotspot on CFTR for potentiation","volume":"364","author":"Liu","year":"2019","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"102542","DOI":"10.1016\/j.isci.2021.102542","article-title":"Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator","volume":"24","author":"Laselva","year":"2021","journal-title":"iScience"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1021\/acs.biochem.3c00165","article-title":"Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs","volume":"62","author":"Lester","year":"2023","journal-title":"Biochemistry"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jcf.2020.04.014","article-title":"Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation","volume":"19","author":"Berkers","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.phrs.2015.08.012","article-title":"Inhibition of intestinal chloride secretion by piperine as a cellular basis for the anti-secretory effect of black peppers","volume":"100","author":"Pongkorpsakol","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"30754","DOI":"10.1074\/jbc.M109.056010","article-title":"Curcumin cross-links cystic fibrosis transmembrane conductance regulator (CFTR) polypeptides and potentiates CFTR channel activity by distinct mechanisms","volume":"284","author":"Bernard","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1021\/ci800420z","article-title":"Influence of protonation, tautomeric, and stereoisomeric states on protein-ligand docking results","volume":"49","author":"Exner","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/ci800298z","article-title":"Empirical scoring functions for advanced protein-ligand docking with PLANTS","volume":"49","author":"Korb","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/jcph.1999.6201","article-title":"NAMD2: Greater Scalability for Parallel Molecular Dynamics","volume":"151","author":"Skeel","year":"1999","journal-title":"J. Comput. Phys."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J. Comput. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1021\/jp973084f","article-title":"All-atom empirical potential for molecular modeling and dynamics studies of proteins","volume":"102","author":"MacKerell","year":"1998","journal-title":"J. Phys. Chem. B"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","volume":"31","author":"Vanommeslaeghe","year":"2010","journal-title":"J. Comput. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/jcc.21816","article-title":"SwissParam: A fast force field generation tool for small organic molecules","volume":"32","author":"Zoete","year":"2011","journal-title":"J. Comput. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: Visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1021\/acs.jcim.7b00650","article-title":"KDEEP: Protein-Ligand Absolute Binding Affinity Prediction via 3D-Convolutional Neural Networks","volume":"58","year":"2018","journal-title":"J. Chem. Inf. Model."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/552\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:45:12Z","timestamp":1760132712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/1\/552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,31]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["ijms25010552"],"URL":"https:\/\/doi.org\/10.3390\/ijms25010552","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2023,12,31]]}}}